Dose-ranging study of ST-290, an AAV2/6 Human Alpha Galactosidase – a gene therapy in subjects with Fabry disease

DOSE-RANGING STUDY OF ST-920, AN AAV2/6 HUMAN ALPHA GALACTOSIDASE A GENE THERAPY IN SUBJECTS WITH FABRY DISEASE